AI assistant
Atea Pharmaceuticals, Inc. — Director's Dealing 2022
Nov 16, 2022
33577_dirs_2022-11-15_ef02cbda-2af2-4479-a6be-c9f437496c82.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2022-11-11
Reporting Person: BERGER FRANKLIN M (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-11-11 | Common Stock | S | 25500 | $5.1503 | Disposed | 794519 | Direct |
| 2022-11-14 | Common Stock | S | 16166 | $5.156 | Disposed | 778353 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.1200 to $5.1947, inclusive.
F2: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.1000 to $5.2242, inclusive.